New cardiac stem cells which have great treatment potential

Researchers from North Carolina State University and the First Affiliated Hospital of Zhengzhou University in China have developed a new version of a new cardiac stem cell (CSC), according to a new study involving recombinant mouse proteins and it has been published in the International Journal of Nature Communications. These synthetic cells can provide therapeutic potential compared to natural stem cells, while reducing the risk of disease associated with stem cell therapy. In addition, the new stem cells developed by the researchers also have some stability, and this technology is expected to help to develop other types of stem cells.

Stem cell therapy can play a role in promoting endogenous repair of the body, that is, it can repair damaged tissues by secreting paracrine factors, including proteins and genetic material. When stem cells therapies can be effective in the treatment of disease, they often tend to induce tumor growth and immune rejection. What's worse, these stem cells themselves are very fragile. Before being used, they need to conduct a series of important processes.

"We developed a new version of heart stem cells, and these stem cells can be used in a variety of off-the-shelf applications," said Ke Cheng, co-author of the study. Researchers have developed a cell-derived microparticle (CMMP) that utilizes poly (lactic-co-glycolic acid) (PLGA). PLGA is a biodegradable and biocompatible polymer. Then researchers obtained growth factor protein from human heart stem cells and added this growth factor protein to PLGA, finally successfully covering these PLGA particles with the heart stem cell membrane. "We can package 'cargo' and stem cell shells into biodegradable particles," Cheng said.

In vitro, both CMMP and heart stem cells have been shown to promote cardiac muscle cell growth. CMMP has also been tested in a mouse model of myocardial infarction and found that CMMP binds to cardiac tissue and can promote growth after the onset of heart disease, and this effect is considerable with the repair role of heart stem cells. Due to a special structure, CMMP can't replicate, which reduces the risk of tumor formation.

The researchers pointed out that these new synthetic cells have the same principle with inactivated vaccines. While outer membrane structure can also help to bypass the body's immune response, which combine with the heart tissue, releasing special growth factors for repair. But these new stem cells can't self-replicate, so it will be able to repair the body tissue to produce a stable effect while at the same time with lower risk. These new stem cells are more durable than human stem cells and are well tolerated by repeated freezing and thawing. Scientists don't necessarily have to acquire these cells from human cells. The development of these cells is also applicable in other stem cells.

Finally, the authors hope that this study will provide a new basis for the development of more novel stem cell products in the future, and the development of new stem cell products will of course provide beneficial stem cell therapy for patients while reducing the risk of other complications. Flarebio provides you with recombinant proteins of good quality such as recombinant CDH2.